Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05459571 · ClinicalTrials.gov registry record · Phase 2
Study of Axicabtagene Ciloleucel Given With Steroids In Participants With Relapsed Or Refractory Large B-Cell Lymphoma
A Phase 2 study of Relapsed or Refractory Large B-cell Lymphoma, sponsored by Kite, A Gilead Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
- 16
- Study locations
NCT05459571: Completed Phase 2 study of Relapsed or Refractory Large B-cell Lymphoma, sponsored by Kite, A Gilead Company.
NCT05459571 is a Phase 2 study of Relapsed or Refractory Large B-cell Lymphoma that has completed, run by Kite, A Gilead Company. The registered enrollment target is 35 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (74% lower). The trial reports 16 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05459571, a Phase 2 study of Relapsed or Refractory Large B-cell Lymphoma, has completed, sponsored by Kite, A Gilead Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
- 16
- Study locations
Study Summary
The goal of this clinical study is to learn more about the study drug, axicabtagene ciloleucel, in participants with relapsed or refractory large B-cell lymphoma (LBCL) in the outpatient setting.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- DRUG Dexamethasone
- BIOLOGICAL Axicabtagene Ciloleucel
Study Locations (16)
Virginia
- University of Virginia Health System - Charlottesville
- Virginia Oncology Associates - Norfolk
- Virginia Commonwealth University - Richmond
California
- City of Hope (City of Hope National Medical Center, City of Hope Medical Center) - Duarte
- UCLA - Los Angeles
Tennessee
- Tennessee Oncology, PLLC - Nashville
- Henry-Joyce Cancer Clinic - Nashville
Utah
- Intermountain Healthcare - Murray
- Huntsman Cancer Institute, University of Utah - Salt Lake City
Colorado
- Colorado Blood Cancer Institute - Denver
Maryland
- University of Maryland Greenebaum Comprehensive Cancer Center - Baltimore
Michigan
- Barbara Ann Karmanos Cancer Institute - Detroit
New Jersey
- John Theurer Cancer Center at Hackensack University Medical Center - Hackensack
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2022-08-09 |
| Est. Completion | 2025-11-24 |
| Phase | Phase 2 |
What the finished NCT05459571 record still lists
NCT05459571 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (74% lower).
The record links to 1 condition, with Relapsed or Refractory Large B-cell Lymphoma appearing as the primary indexed condition, and to 4 interventions - of which Cyclophosphamide is the first listed.
NCT05459571 lists 16 locations in 11 states (Virginia, California, Tennessee).
Frequently Asked Questions
What is clinical trial NCT05459571 about?
NCT05459571 is a clinical study titled "Study of Axicabtagene Ciloleucel Given With Steroids In Participants With Relapsed Or Refractory Large B-Cell Lymphoma". The goal of this clinical study is to learn more about the study drug, axicabtagene ciloleucel, in participants with relapsed or refractory large B-cell lymphoma (LBCL) in the outpatient setting.
What is the current status of trial NCT05459571?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2022-08-09. Estimated completion is 2025-11-24.
What conditions does trial NCT05459571 study?
This clinical trial studies the following conditions: Relapsed or Refractory Large B-cell Lymphoma.
What interventions are being tested in trial NCT05459571?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), Dexamethasone (DRUG), Axicabtagene Ciloleucel (BIOLOGICAL).
Who is sponsoring clinical trial NCT05459571?
This trial is sponsored by Kite, A Gilead Company, which has 28 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05459571 being conducted?
This trial has 16 study locations across California, Colorado, Maryland, Michigan, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsed or Refractory Large B-cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05459571's enrollment target sits among peer trials
35 1524th of 2000 higher than 462 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI